PPI network analysis identified core targets such as MAPK3, STAT3, AKT1, PRKACA, MAPK1, and TNF, suggesting BCBL's efficacy in depression treatment may stem from its action on multiple key targets. This evidence concerns the gene AKT1 and depressive symptom measurement.